Neumora Therapeutics (NMRA) Cash & Equivalents (2022 - 2026)
Neumora Therapeutics (NMRA) recorded Cash & Equivalents of $116.83 million in Q2 2026, down 6.2% from $124.52 million a year earlier and down 20.6% from the prior quarter.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Cash & Equivalents (2022 - 2026) Analysis & Trends
At the end of FY2025, Neumora Therapeutics reported Cash & Equivalents of $182.53 million, up 28.4% from FY2024.
- Annual Cash & Equivalents has a three-year compound annual growth rate of -8.8% (FY2022 to FY2025).
- Across earlier years, Cash & Equivalents came in at $142.15 million in FY2024 (-62.0%), $374.04 million in FY2023 (+55.2%) and $240.94 million in FY2022.
- The Q2 2026 figure is the lowest quarterly Cash & Equivalents in data going back to Q3 2022.
- On a year-over-year basis, Cash & Equivalents rose in two of the last eight quarters, with an average decline of 19.8%.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 63.3% in Q3 2023, against a decline of 62.0% in Q4 2024 at the low end.
- Per Business Quant, the preceding three quarters came in at $147.07 million (Q1 2026), $182.53 million (Q4 2025) and $129.07 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.66 Bn | 1,106.24 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 636.13 Bn | 556.00 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 505.28 Bn | 478.39 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 358.10 Bn | 312.48 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 292.59 Bn | 256.58 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 265.81 Bn | 239.50 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 237.53 Bn | 192.93 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 171.17 Bn | 117.82 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Neumora Therapeutics | 69.36 Mn | -548.60 Mn | - | 116.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 116.83 Mn |
| Mar 31, 2026 | 147.07 Mn |
| Dec 31, 2025 | 182.53 Mn |
| Sep 30, 2025 | 129.07 Mn |
| Jun 30, 2025 | 124.52 Mn |
| Mar 31, 2025 | 126.86 Mn |
| Dec 31, 2024 | 142.15 Mn |
| Sep 30, 2024 | 275.71 Mn |
| Jun 30, 2024 | 150.68 Mn |
| Mar 31, 2024 | 182.93 Mn |
| Dec 31, 2023 | 374.04 Mn |
| Sep 30, 2023 | 412.28 Mn |
| Jun 30, 2023 | 204.22 Mn |
| Mar 31, 2023 | 210.87 Mn |
| Dec 31, 2022 | 240.94 Mn |
| Sep 30, 2022 | 252.51 Mn |
API Access
Neumora Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=NMRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "NMRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=NMRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();